Compare XBIT & ARAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIT | ARAI |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | 85 | N/A |
| Industry | Pharmaceuticals and Biotechnology | Diversified Commercial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 35.0M |
| IPO Year | 2015 | N/A |
| Metric | XBIT | ARAI |
|---|---|---|
| Price | $2.43 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 42.9K | ★ 19.0M |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $900.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $0.51 |
| 52 Week High | $3.61 | $15.50 |
| Indicator | XBIT | ARAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 51.40 |
| Support Level | $2.15 | $0.51 |
| Resistance Level | $2.46 | $1.13 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 70.83 | 41.65 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advanced chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.